Kezar Life Sciences (NASDAQ:KZR) Stock Rating Reaffirmed by Cowen

Cowen reaffirmed their buy rating on shares of Kezar Life Sciences (NASDAQ:KZR) in a research report released on Wednesday morning, AnalystRatings.com reports.

KZR has been the subject of several other research reports. Zacks Investment Research cut shares of Kezar Life Sciences from a buy rating to a hold rating in a research report on Wednesday, October 9th. ValuEngine raised shares of Kezar Life Sciences from a hold rating to a buy rating in a research report on Thursday, August 1st. Finally, HC Wainwright reissued a buy rating and issued a $15.00 price target on shares of Kezar Life Sciences in a research report on Monday, October 21st. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Kezar Life Sciences currently has a consensus rating of Buy and a consensus target price of $9.25.

Shares of KZR traded down $0.03 during mid-day trading on Wednesday, hitting $2.89. 27,200 shares of the company were exchanged, compared to its average volume of 94,239. The company has a debt-to-equity ratio of 0.06, a quick ratio of 20.32 and a current ratio of 20.32. The stock has a market cap of $55.12 million, a price-to-earnings ratio of -1.28 and a beta of 0.88. The company has a 50 day moving average of $3.28 and a 200-day moving average of $7.82. Kezar Life Sciences has a 1-year low of $2.74 and a 1-year high of $36.33.

Kezar Life Sciences (NASDAQ:KZR) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.48) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.51) by $0.03. Research analysts anticipate that Kezar Life Sciences will post -1.96 earnings per share for the current fiscal year.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Metropolitan Life Insurance Co NY acquired a new stake in shares of Kezar Life Sciences in the 1st quarter valued at $89,000. Northern Trust Corp raised its holdings in shares of Kezar Life Sciences by 4.6% in the 2nd quarter. Northern Trust Corp now owns 132,888 shares of the company’s stock valued at $1,025,000 after purchasing an additional 5,882 shares in the last quarter. Ironsides Asset Advisors LLC raised its holdings in shares of Kezar Life Sciences by 50.0% in the 2nd quarter. Ironsides Asset Advisors LLC now owns 17,650 shares of the company’s stock valued at $136,000 after purchasing an additional 5,886 shares in the last quarter. Charles Schwab Investment Management Inc. raised its holdings in shares of Kezar Life Sciences by 24.3% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 35,057 shares of the company’s stock valued at $271,000 after purchasing an additional 6,854 shares in the last quarter. Finally, Marshall Wace LLP raised its holdings in shares of Kezar Life Sciences by 33.7% in the 2nd quarter. Marshall Wace LLP now owns 53,016 shares of the company’s stock valued at $409,000 after purchasing an additional 13,353 shares in the last quarter. Institutional investors and hedge funds own 52.28% of the company’s stock.

About Kezar Life Sciences

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the United States. Its lead product candidate, KZR-616, a selective immunoproteasome inhibitor that is in Phase 1b/2 clinical trials in lupus and lupus nephritis.

Featured Story: Stop Order Uses For Individual Investors

Receive News & Ratings for Kezar Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kezar Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit